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Activated mast cells, eosinophils, and basophils infiltrate the airways of asthmatics as a result of an overex-
uberant T helper 2 (Th2) cell immune response that drives the production of IgE, primes mast cells and baso-
phils, and promotes tissue eosinophilia and mast cell hyperplasia. Recent evidence demonstrates that these
innate effectors can be activated outside of this classical Th2 cell paradigm and that they have additional
roles in promoting the development of innate and adaptive pulmonary inflammation. There is also an appre-
ciation for the role of airway epithelial cells in orchestrating allergic pulmonary inflammation. Emerging data
from basic research highlight the involvement of many unique pathways in the inflammation triggered by
complex native allergens and microbes at the airway mucosal surface. Here, we review the role of effector
cells and airway epithelial cells in augmenting and, at times, bypassing traditional Th2 cell-mediated allergic
inflammation.Introduction
Airway inflammation, reversible airflow obstruction, and an
increased sensitivity to nonspecific irritants or bronchoconstrict-
ing agents, termed airway hyperresponsiveness (AHR), are the
cardinal features of asthma. Although inflammation had been
noted in asthmatic airway biopsies since the 1960s, it was not
until the advent of the flexible bronchoscope that inflammation
was recognized as a consistent feature of the asthmatic airway,
seen even in mild, newly diagnosed adult and pediatric patients.
Analysis of the cellular infiltrate in bronchial biopsies and bron-
choalveolar lavage (BAL) of asthmatic patients demonstrated
the presence of eosinophils, degranulated mast cells (MCs),
and T helper 2 (Th2) lymphocytes generating interleukin-3
(IL-3), IL-4, IL-5, IL-9, IL-13, and granulocyte macrophage
colony-stimulating factor (GM-CSF) (Bousquet et al., 2000; Rob-
inson et al., 1992), which differentiated asthma from chronic
obstructive pulmonary disease and focused research in airway
inflammation for the ensuing decade.
The Th2 Cell Paradigm
The specific contribution of Th2 lymphocytes to asthma was
noted in studies comparing Th2 lymphocyte infiltration to indices
of airflow obstruction or clinical course. Classical allergen chal-
lenge studies, in which aerosolized allergen is given to sensitized
asthmatics, demonstrate airflow obstruction, as measured by
a fall in forced expiratory volume in 1 min (FEV1) that begins
within several minutes, peaks by 30 min, and improves over
several hours. This ‘‘early phase’’ response is followed by a
second fall in FEV1 hours later, the ‘‘late phase.’’ Both phases
are blocked by pretreatment with inhibitors of MC degranulation
or MC-derived bronchoconstricting mediators; however, the late
phase is uniquely associated with an influx of eosinophils and T
lymphocytes and an increase in Th2 cell cytokines in the BAL and
bronchial mucosa. Furthermore, asthma severity correlates with
the extent of T cell infiltration in the BAL, and persistent lympho-cyte activation is seen in some patients with refractory steroid-
resistant asthma (reviewed in Kay, 1997).
Mouse models of antigen-induced pulmonary inflammation
have also supported a central role for Th2 cells and their cyto-
kines. Adoptive transfer of TCR-transgenic Th2 cells, but not
Th1 cells, from DO11.10 mice and subsequent ovalbumin
(OVA) challenge of recipients induces eosinophilic airway inflam-
mation and AHR (Cohn et al., 1997; Cohn et al., 1998), and deple-
tion of CD4+ T cells prior to challenge prevents both of these
responses in OVA sensitized and challenged wild-type (WT)
mice (Gavett et al., 1994). Furthermore, sensitization and airway
challenge studies of mice with transgenic overexpression of
cytokines, targeted deletion of cytokines, or blocking cytokine
antibodies have demonstrated a central role for IL-4 in the gener-
ation of Th2 cells and IgE; for IL-5 in the promotion of airway
eosinophilia; for IL9 in the recruitment, proliferation, and differen-
tiation of MCs; and for IL-13 in induction of AHR, goblet cell
metaplasia, and mucin production (reviewed in Holgate and
Polosa, 2008). These studies have led to the dominant thesis
that activated Th2 cells orchestrate the pulmonary immune
response, stimulate B cell production of allergen-specific IgE,
and elicit the structural changes in the lung that are seen in asth-
matic patients.
Despite the strength of the Th2 cell paradigm, some features
of human asthma are not been well explained by it alone. First,
neutrophilic inflammation on bronchial biopsy is common in
asthmatics, the degree of neutrophilia is roughly correlated
with asthma severity, and neutrophilic inflammation without
eosinophils is seen in a substantial subgroup of severe cortico-
steroid-dependent asthmatics, underscoring the heterogeneity
of disease (Wenzel et al., 1999). Second, the histopathologic
features of airway inflammation—including eosinophil influx
and degranulated MCs—are similar in ‘‘intrinsic’’ asthma, in
which there is no allergic trigger of symptoms, no family or
personal history of atopy, and no evidence of allergen-specificImmunity 31, September 18, 2009 ª2009 Elsevier Inc. 425
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additional pathways may be triggering the inflammation. Third,
even in well-phenotyped allergic asthmatics, the administration
of antibodies that prevent the binding of IgE to Fc3RI or that
neutralize IL-5 has had limited therapeutic efficacy and the
success of interventions directed against IL-4 and IL-13 is, as
yet, unproven (Holgate and Polosa, 2008). Fourth, viral infections
are a common trigger for exacerbation in both atopic and nona-
topic asthma. Finally, the antigen-induced AHR in the late phase
of allergen challenge in human asthma or in sensitized and chal-
lenged mice is susceptible to inhibitors that are not capable of
ameliorating the ‘‘intrinsic’’ or inflammation-independent AHR
of the human disease. These observations suggest that addi-
tional mechanisms, beyond the classical activation of Th2
lymphocytes or crosslinking of IgE, may exist to drive neutro-
philic and eosinophilic airway inflammation.
Beyond Th2 Cells
Although traditional mouse models of antigen-induced pulmo-
nary inflammation that use intraperitoneal (i.p.) OVA sensitization
(with or without aluminum hydroxide) and intranasal (i.n.), intra-
tracheal (i.t.), or aerosolized OVA challenge have been instruc-
tive, they do not include the participation of a full mucosal
immune response comparable to complex allergens such as
dust mites or molds that contain protease activity and/or innate
pattern-recognition receptor ligands for the Toll-like receptor
(TLR), C-type lectin receptor (CLR), and/or nucleotide-binding
domain, leucine-rich repeat-containing protein (NLR) families
that facilitate their immunogenicity. Recent studies in mice with
airway delivery of native allergens or respiratory viruses have un-
derscored the critical role of innate signaling in the generation of
allergic pulmonary inflammation and the complex immunologic
response that includes the participation of Th1, Th2, Th17,
NKT, and airway epithelial cells (Akbari et al., 2003; Bartlett
et al., 2008; Grayson et al., 2007; Hammad et al., 2009; Kim
et al., 2008; Phipps et al., 2009). In this review, we will discuss
the role of the epithelial cell-derived cytokines IL-25, TSLP,
and IL-33 as orchestrators of eosinophilic airway inflammation
and the contribution of NKT cells to AHR. We will then review
newly described functions for the classic effector cells, MCs,
eosinophils, and basophils. In each section, we will highlight
emerging data on the role of these innate cytokines and cells in
augmenting and, at times, bypassing traditional Th2 cell-medi-
ated allergic inflammation.
Epithelial Cell-Derived Cytokines: IL-25
IL-25 is a member of the IL-17 cytokine family but has limited
homology to IL-17A (17%), uses IL17RB rather than the
IL17RA and IL17RC heterodimer, and has distinct biologic
functions. Although IL-25 was initially reported as a product of
differentiated murine Th2 cells (Fort et al., 2001), IL-25 is made
by activated eosinophils, by bone marrow-derived mast cells
(BMMCs) and basophils after Fc3RI-mediated activation, and
by epithelial cells in response to allergens such as Aspergillus
oryzae, Aspergillus fumigatus, ragweed, and the house dust
mite, Dermatophagoides pteronyssinus (Dp) (Hammad et al.,
2009 and reviewed in Saenz et al., 2008). Thus, IL-25 generation
is induced in both innate and adaptive immune responses to
allergens.426 Immunity 31, September 18, 2009 ª2009 Elsevier Inc.IL-25 acts on both recruited hematopoietic cells and native
resident cells in the lung. IL-25 promotes the differentiation of
murine Th2 cells in an IL-4- and STAT6-dependent manner
in vitro (Angkasekwinai et al., 2007). IL-17RB is expressed on
murine CD4+ invariant NKT (iNKT) cells in which it identifies
a potent IL-4- and IL-13-producing subset that, on adoptive
transfer, can reconstitute AHR in sensitized and challenged
iNKT cell-deficient mice (Terashima et al., 2008) (see NKT Cells).
OVA-alum sensitization and OVA aerosol challenge of mice with
the transgenic overexpression of IL-25 elicits elevated BAL
eosinophils, IL-4, IL-5, and IL-13, which is abrogated with anti-
CD4 prior to challenge or with crossing to Stat6/ mice (Tama-
chi et al., 2006), suggesting that CD4+ Th2 cells can mediate
IL-25 effects in vivo. In an early report of IL-25 function in vivo
(Hurst et al., 2002), WT and Rag1/ mice treated with recombi-
nant IL-25 (rIL-25) or an adenoviral construct expressing IL-25
generated high levels of IL-5 and IL-13 transcripts in the spleen,
suggesting that a non-B/non-T (NBNT) cell could also mediate
production of Th2 cytokines in response to IL-25. The i.n. admin-
istration of murine rIL-25 into C57BL/6 WT mice generates BAL
eosinophilia and whole lung IL-5, IL-13, and eotaxin transcripts
24 hr later, each of which is significantly reduced in mice with
an epithelial-specific knockout of Act1, an adaptor protein
required for IL-17RB signaling, identifying a pathway for an
epithelial cell response (Swaidani et al., 2009). Thus, IL-25 acts
on an unusual range of hematopoietic and stromal cells to influ-
ence both innate and adaptive pulmonary inflammation.
Studies that use overexpression of IL-25 or administration of
rIL-25 have consistently demonstrated a capacity for induction
of Th2 cytokines and eosinophilia. Systemic administration of
rIL-25 for 10 days in C57BL/6 mice induced peripheral blood
eosinophilia, splenomegaly, eosinophilic infiltration of the spleen
and lung, pulmonary goblet cell metaplasia, medial hypertrophy
of the small and medium-sized pulmonary arteries, and elevated
serum IgG1, IgA, and IgE, among other abnormalities (Fort et al.,
2001). Adenoviral vector-mediated overexpression of IL-25 led
to similar immunoglobulin abnormalities and histologic changes
in the lungs with the addition of perivascular fibrosis. Il4ra/ and
Il13/ mice infected with the same construct were protected
from mucus production and goblet cell metaplasia, Il4ra/
and Il4/mice were protected from the increased immunoglob-
ulin levels and pulmonary vascular changes, and WT mice
treated with anti-IL-5 were protected from peripheral blood
eosinophilia, demonstrating that IL-25-dependent pathology is
mediated entirely through downstream Th2 cytokines. Studies
using the transgenic overexpression of murine IL-25 or IL-25
adenoviral vector infection reported similar abnormalities as
well as elevations in circulating or BAL neutrophils (reviewed in
Wang and Liu, 2009). Lastly, a recent study has shown that
matrix matalloproteinase 7, an enzyme induced in allergen-acti-
vated airway epithelial cells, can both augment levels of IL-25 as
well as cleave it to a more active form to promote Th2 cytokine
production (Goswami et al., 2009).
Several studies have addressed the role of IL-25 in murine
models of antigen-induced pulmonary inflammation and AHR.
Balb/c mice sensitized with i.p. OVA-alum and challenged with
aerosolized OVA have an upregulation of IL-25 transcript in the
lung and eosinophils, CD4+ T cells, and IL-5 and IL-13 protein
in the BAL, each of which is reduced in mice treated with
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lenge (Tamachi et al., 2006). The administration of anti-IL-25 to
WT Balb/c mice prior to OVA-alum sensitization and prior to
OVA aerosol challenge decreased AHR, pulmonary cellular
infiltrate, BAL eosinophilia, OVA-specific serum IgE, and IL-5
and IL-13 generated by restimulation of parabronchial lymph
node cells with OVA ex vivo (Ballantyne et al., 2007). Interest-
ingly, when mice were treated with anti-IL-25 only during the
OVA aerosol challenge phase, AHR was abolished and IL-5
and IL-13 levels in the BAL were diminished, but pulmonary
cellular infiltrate and goblet cell metaplasia, OVA-specific serum
IgE, and Th2 cytokines from restimulation of parabronchial LN
cells with OVA ex vivo were intact. Direct intranasal injection of
IL-25 elicited AHR in Balb/c WT, Il13/, and Il4/Il5/Il9/
Il13/ strains, suggesting an independent effect of IL-25. Taken
together, murine in vitro and in vivo studies suggest that IL-25
can potentiate the induction of Th2 cell airway inflammation in
the sensitization phase, can amplify Th2 inflammation in the
challenge phase, and can induce AHR in the absence of Th2
cytokines.
There is limited data on the role of IL-25 in human asthma.
IL-25 potentiates the proliferation of CD4+CD45RO+CRTH2+
human Th2 memory cells and augments their production of
IL-4, IL-5, and IL-13 (Wang et al., 2007). IL-17RB protein is
expressed on cultured primary human airway smooth muscle
cells (Lajoie-Kadoch et al., 2006), on human fibroblast cell lines
(Le´tuve´ et al., 2006), and on human peripheral blood mono-
cyte-derived macrophages cultured in the presence of IL-4 or
IL-4 and TGF-b (Gratchev et al., 2004). Cultured human periph-
eral blood eosinophils also express IL-17RB that mediates
production of IL-6, IL-8, MIP-1a, and MCP-1, prevents eosino-
phil apoptosis, and alters eosinophil adhesion proteins with an
upregulation of ICAM-1 and a downregulation of ICAM-3 and
L-selectin (Cheung et al., 2006; Wong et al., 2005). Bronchial
biopsies of patients with asthma show elevations of IL-25 and
IL-17RB transcripts as compared to normal controls. Immuno-
histochemical studies have also shown IL-25 protein in submu-
cosal inflammatory cells of asthmatic bronchial biopsies (Le´tuve´
et al., 2006), supporting a role for this mediator in human disease.
Epithelial Cell-Derived Cytokines: IL-33
IL-33 is a member of the IL-1 cytokine family. RT-PCR from
human and mouse cDNA libraries have shown IL-33 transcript
in murine and human epithelial cells, DCs, and activated macro-
phages and in human bronchial smooth muscle (Schmitz et al.,
2005). In a murine model of antigen-induced pulmonary inflam-
mation, intracellular cytokine staining revealed IL-33 in alveolar
CCR3-F4/80+ myeloid cells (Kurowska-Stolarska et al., 2008),
whereas in a model with direct i.t. administration of house dust
mite, Dp, IL-33 protein in the BAL was recovered from WT
mice, but not Tlr4/ mice or bone marrow chimeras with WT
reconstitution of Tlr4/ mice (Hammad et al., 2009), suggesting
there are multiple cellular sources during both the innate and
adaptive immune components of allergic inflammation.
IL-33 acts at the Toll/interleukin-1 (TIR) domain-containing
receptor ST2. Soluble and transmembrane forms of the receptor,
produced by differential mRNA splicing, act as a soluble decoy
or transmembrane activator, respectively (see below). IL-33
can activate murine BMMCs to release TNF-a, IL-1b, IL-6,IL-13, Rantes, GM-CSF, MCP-1, MIP1-a, and MIP1-b (Ali
et al., 2007; Ho et al., 2007; Kondo et al., 2008) and can activate
murine bone marrow-derived basophils to produce IL-6, IL-4,
IL-9, IL-13, Rantes, and MCP-1 (Kondo et al., 2008; Kroeger
et al., 2009). Stimulation of committed murine Th2 cells with
IL-33 elicits production of IL-4, IL-5, and IL-13 (Coyle et al.,
1999; Kondo et al., 2008; Lohning et al., 1998), whereas stimula-
tion of naive purified CD4+CD62L+ DO11.10 T cells with IL-33
induces the generation of Th2 cells in a manner dependent on
ST2 and MyD88 signaling, but independent of IL-4, IL-4Ra,
and STAT6 (Kurowska-Stolarska et al., 2008). These in vitro
studies emphasize that IL-33 can promote Th2 cell immunity
through both the direct activation of innate effector cells and
the generation and activation of IL-4-independent, MyD88-
dependent Th2 cells.
Several studies have demonstrated a role for ST2 (encoded by
Il1r1) in Th2 cell pulmonary inflammation. In models using direct
OVA-alum sensitization and OVA aerosol or intranasal challenge,
Il1rl1/ mice on a Balb/c background had reduced eosinophilia
and IL-5 in the BAL and reduced cellular influx into the lung
(Kurowska-Stolarska et al., 2008). Similarly, administration of
the ST2-specific mAb prior to the sensitization and challenge
of WT Balb/c mice attenuated eosinophilia and IL-5 levels in
the BAL, as well as serum OVA-specific IgE (Coyle et al.,
1999). Two murine studies using adoptive transfer of Th2 cells
from DO11.10 mice into WT recipients with subsequent OVA
aerosol challenge have shown reductions in induced AHR, BAL
eosinophilia, and BAL concentrations of IL-4, IL-5, IL-6, and
IL-13 with the administration of either an ST2-specific mAb or
an ST2-IgG soluble fusion protein prior to each OVA challenge
(Coyle et al., 1999; Lohning et al., 1998), emphasizing a role for
this pathway in the challenge phase. When WT or Il4/ mice
were subjected to an OVA-alum sensitization and OVA challenge
protocol with only 10 ug of OVA for sensitization, the addition of
exogenous IL-33 during sensitization triggered similar BAL
eosinophilia, pulmonary inflammation, goblet cell metaplasia,
and IL-5-producing CD4+ST2+ T cells upon challenge (Kurow-
ska-Stolarska et al., 2008), thereby demonstrating that IL-33
can specifically promote IL-4-independent Th2 cells that partic-
ipate in antigen-induced immune responses. In a pharmacologic
study, repeated i.p. injection of rIL-33 induced goblet cell meta-
plasia and AHR to methacholine in Balb/c WT and Rag2/ mice
similarly, demonstrating that the direct actions of IL-33 on innate
effector cells can bypass the requirement for Th2 cells (Kondo
et al., 2008). Lastly, studies using OVA-alum sensitization and
OVA challenge with higher doses of antigen (100 mg) or longer
protocols (28 days) have not shown a dependence on ST2
signaling (Hoshino et al., 1999; Kurowska-Stolarska et al.,
2008), indicating that the IL33-ST2 pathway can be bypassed
with continued immune stimulation. In sum, murine in vitro and
in vivo studies demonstrate that IL-33 acts in the effector phase
to augment Th2 cytokine production and inflammation via direct
effects on both Th2 cells and innate effectors and can generate
AHR and goblet cell metaplasia in the absence of adaptive
immunity.
In studies of human cells, IL-33 stimulation potentiates the
production of IL-4, IL-5, and IL-13 from CD3+CRTH2+ Th2 cells
in the peripheral blood and from cord blood CD4+ cells activated
by anti-CD3 and anti-CD28 (Kurowska-Stolarska et al., 2008;Immunity 31, September 18, 2009 ª2009 Elsevier Inc. 427
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cultured from peripheral blood or cord blood-derived CD34+
MC progenitors to generate IL-5, IL-13, GM-CSF, TNF-a,
IL-10, IL-6, CXCL8, and CCL1, without degranulation or the
production of prostaglandin D2 or leukotriene C4 (LTC4) (Allakh-
verdi et al., 2007b). IL-33 can increase CD11b expression and
enhance the survival of freshly isolated human peripheral blood
eosinophils in an ST2-dependent fashion without degranulation
or LTC4 synthesis. IL-33 can also augment production of IL-8
by human eosinophils in response to IL-3, IL-5, and GM-CSF
(Pecaric-Petkovic et al., 2009). ST2 is expressed by purified
human basophils primed with IL-3 (Suzukawa et al., 2008), and
IL-33 stimulation can increase basophil production of IL-4,
expression of ICAM-1, VCAM-1, and CD11b, and release of
histamine in response to Fc3RI crosslinking (Suzukawa et al.,
2008). Asthmatics have a baseline increase in serum ST2 levels
as compared to normal controls, and there is a marked increase
in these levels during asthma exacerbations. ST2 levels correlate
inversely with peak expiratory flow, suggesting elaboration of a
soluble trap for IL-33 with exacerbations in these atopic patients
(Oshikawa et al., 2001).
Epithelial Cell-Derived Cytokines: TSLP
Thymic stromal lymphopoietin (TSLP) is an IL-7-like cytokine
initially cloned from a murine thymic epithelial cell line and iden-
tified as a factor that supported the in vitro development of T and
B cells (Friend et al., 1994; Sims et al., 2000). TSLP protein is de-
tected in human bronchial epithelial cell cultures after stimulation
with dsDNA, rhinovirus, peptidoglycan, or the combination of
IL1b and TNF-a (Allakhverdi et al., 2007a; Kato et al., 2007)
and in the BAL of WT mice after the i.t. administration of the
house dust mite, Dp (Hammad et al., 2009). TSLP transcript is
generated after mAb-mediated Fc3RI crosslinking on human
CD34+ cell-derived MCs (Soumelis et al., 2002). TSLP protein
is generated in murine basophil cultures after IgE crosslinking
or in an innate response to proteolytically active papain (Sokol
et al., 2008). Thus, TSLP can be produced in response to aller-
gens, viruses, cytokines, and PAMPs in the setting of innate or
adaptive immune responses.
TSLP stimulates human peripheral blood CD11c+ DCs to upre-
gulate the expression of HLA-DR and costimulatory molecules
(CD40, CD80, CD86, and CD83) and to generate TARC and
MDC, but not IL-12 p70, type I interferons, or the proinflamma-
tory cytokines IL-1b, IL-6, and TNF-a (Soumelis et al., 2002).
TSLP-treated DCs prime human naive CD4+ T cells to produce
IL-4, IL-5, IL-13, and TNF-a (Liu, 2006; Soumelis et al., 2002).
The upregulation of OX40L on TSLP-treated DCs is central to
their role in Th2 differentiation, given that this function is abro-
gated in the presence of OX40L neutralizing antibodies (Ito
et al., 2005; Seshasayee et al., 2007). TSLP can also act directly
on T cells to enhance Th2 cytokine production, as illustrated in
a model of atopic dermatitis with i.p. OVA sensitization and epi-
cutaneous OVA challenge in which the administration of TSLP
antibodies prior to OVA challenge had no effect on CD4+T cell
recruitment to the tissue but significantly impaired cutaneous
Th2 cytokine production and eosinophil recruitment (He et al.,
2008). TSLP can also drive the proliferation of TCR-activated
human CD4+ T cells (Omori and Ziegler, 2007; Rochman et al.,
2007). In conjunction with IL-1b and TNF-a, TSLP is a potent428 Immunity 31, September 18, 2009 ª2009 Elsevier Inc.stimulus for human cord blood- or peripheral blood-derived
MCs to generate IL-5, IL-13, IL-6, GM-CSF, IL-10, CXCL8, and
CCL1 (Allakhverdi et al., 2007a). Thus, the diverse cell sources
and functions recognized in vitro for TSLP suggest that it can
potentiate allergic inflammation via several cellular targets.
Murine studies have highlighted a role for TSLP in Th2 immune
responses in the lung. Mice with transgenic overexpression of
TSLP in airway epithelial cells display spontaneous pulmonary
inflammation with remarkable BAL cellularity and eosinophilia,
pulmonary inflammation with goblet cell metaplasia and perivas-
cular fibrosis, and AHR (Zhou et al., 2005). Conversely, TSLPR
receptor- (TSLPR)-deficient (Crlf2/) mice are protected from
antigen-induced pulmonary inflammation in a model with OVA-
alum i.p. sensitization and OVA aerosol challenge (Zhou et al.,
2005). A second Crlf2/ strain also showed attenuation of
inflammation with OVA sensitization and challenge that could
be reversed by adoptive transfer of WT but not Crlf2/ CD4+
T cells from OVA sensitized donors to the deficient mice prior
to antigen challenge (Al-Shami et al., 2005). TSLP conditions
DCs to express OX40L and treatment of mice with a neutralizing
antibody to OX40L attenuated the serum IgE, pulmonary inflam-
mation, and BAL IL-4, IL-5, and IL13 protein elicited by either
direct intranasal injection of TSLP or by OVA-alum sensitization
and OVA intranasal challenge (Seshasayee et al., 2007). The
OX40L neutralizing antibody was efficacious even when admin-
istered in the challenge phase. Thus, TSLP can regulate both
primary and secondary Th2 cell immune responses.
Biopsies from the mucosa of asthmatic patients show an
elevated number of cells containing TSLP transcript as com-
pared to normal controls (Ying et al., 2005). TSLP transcript is
expressed in neutrophils, macrophages, MCs, epithelial cells,
and endothelial cells, and the number of TSLP+ cells is correlated
with the severity of airflow obstruction, as assessed by FEV1.
Although a supporting role for TSLP in generating, maintaining,
or amplifying human asthma is suggested by the data in mice,
direct translation to human asthma, as for IL-25 and IL-33, awaits
support from further clinical studies and targeted interventions.
NKT Cells
NKT cells recognize both foreign and endogenous glycolipids
presented by the MHC class I (MHC I)-like molecule CD1d on
APCs. Type I iNKT cells express a restricted repertoire of ab
TCRs, with Va24-Ja18 in human and Va14-Ja18 in mice along
with a limited set of Vb chain gene segments, whereas type II
or variant NKT cells utilize more diverse TCRs. iNKT cells recog-
nize a-galactosylceramide (a-GalCer), which is loaded onto a
tetramer to identify iNKT cells by flow cytometric analysis and
is used as a ligand for their activation. In addition, iNKT cells
can be activated by IL-12, IL-18, IL-33, and type 1 interferons
generated from TLR signaling in DCs that amplify weak signals
from endogenous glycolipid-loaded CD1d or bypass the CD1d
requirement entirely (reviewed in Tupin et al., 2007).
Murine studies have demonstrated a role for iNKT cells in
induction of IL-13-dependent AHR. BothCd1d1/mice (lacking
iNKT cells and variant NKT cells) on a Balb/c background or Ja18-
deficient mice (lacking iNKT cells) on a Balb/c or a C57BL/6
background sensitized with i.p. OVA-alum and challenged with
i.n. OVA had diminished AHR, as compared to their WT controls,
that was restored with the transfer of tetramer-purified iNKT
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dent on iNKT cell cytokine production because it was reconsti-
tuted by transfer of tetramer-purified iNKT cells from WT but
not Il4/Il13/ mice into sensitized recipient Ja18-deficient
mice prior to i.n. challenge with OVA. In a protocol of suboptimal
i.p. sensitization with OVA-alum and i.n. challenge with OVA that
used 2 ug of IL-25 for priming prior to OVA challenge, Ja18-defi-
cient mice had attenuated AHR that was uniquely restored with
transfer of a splenic CD4+ iNKT cell subpopulation expressing
IL-17RB (Terashima et al., 2008). Additionally, a recent murine
study of Sendai virus-induced chronic pulmonary inflammation
demonstrated that IL-13-producing CD4 iNKT cells identified
in the lung 21 and 49 days after infection promoted the recruit-
ment and activation of CD68+IL13+ alternatively activated macro-
phages (Kim et al., 2008). Macrophage activation was critical for
subsequent airway goblet cell hyperplasia and AHR in WT mice
and was abrogated in bothCd1d1/ and Ja18-deficient strains.
Thus, iNKT cells, activated in the setting of antigen, proinflamma-
tory cytokines, or viral infection can promote AHR and structural
airway changes, termed airway remodeling.
Notably, studies with B2m/ strains, which also lack iNKT
cells, have not demonstrated an impairment in AHR in immuniza-
tion protocols that are more severe (Brown et al., 1996; Koh
et al., 2008), demonstrating the ability to bypass the iNKT cell
contribution to AHR. Although one study has reported a signifi-
cant decrement in BAL eosinophilia and antigen-specific IgE
after sensitization and challenge of C57 Ja18-deficient mice
(Lisbonne et al., 2003), studies using stronger immunization
protocols in B2m/ mice (Brown et al., 1996; Das et al., 2006;
Koh et al., 2008; Zhang et al., 1996) and in Cd1d1/ mice (Ak-
bari et al., 2003; Das et al., 2006) have not demonstrated any
impairment. Thus, the aggregate studies in B2m/, Cd1d1/,
and Ja18-deficient strains in models of antigen-induced pulmo-
nary inflammation indicate a circumscribed role for NKT cells in
IL-13-dependent AHR (but no clear effect on the cellular infil-
trate) that can be bypassed with stronger protocols.
iNKT cells are <1% of peripheral blood CD4+ cells and <1% of
BAL CD4+ cells in nonasthmatic subjects. An initial study report-
ing a high percentage of CD4+a-GalCer-loaded CD1d tetramer+
cells in the BAL and bronchial biopsies of patients with moderate
to severe asthma has not been duplicated (Akbari et al., 2006;
Thomas et al., 2006; Vijayanand et al., 2007). However, some
increase in CD4+ a-GalCer-loaded CD1d tetramer+ cells was
seen in the BAL of asthmatic children as compared to normal
controls (Pham-Thi et al., 2006), and an increased percentage
of Va24+6B11+ iNKT cells was seen in the BAL of adult
asthmatics, as compared to peripheral blood (Thomas et al.,
2007). Finally, another recent study demonstrated that
CCR9+Va24+ INF-g-producing iNKT cells isolated from the
peripheral blood of asthmatics, but not normal controls, can
direct Th2 cytokine generation from cocultured conventional
CD3+ T cells in a manner dependent on CD226, a member of
the Ig superfamily that mediates cell-cell adhesion (Sen et al.,
2005). This same CCR9+Va24+ IFN-g-producing iNKT cell pop-
ulation was found in the bronchial biopsies of asthmatics, but
not normal controls, and was associated with upregulation of
mucosal Th2 cytokine transcripts as well as the CCR9 ligand
CCL25, suggesting a role for IFN-g-producing iNKT cell in
bronchial asthma.Mast Cells
MCs are well-established effectors in allergic airway inflamma-
tion. Crosslinking of Fc3RI by IgE-bound inhaled antigen can
trigger degranulation, defined by the release of the preformed
secretory granule complex and subsequent extracellular disso-
ciation of preformed mediators (e.g., histamine and certain
proteases). Activation is accompanied by the rapid synthesis
of lipid mediators (e.g., cys-LTs, dihydroxy leukotrienes, and
prostaglandin D2), and the induction of cytokines and chemo-
kines (e.g., IL-4, IL-13, IL-12, IL-1, IL-18, TNF-a, etc.). Through
the sequential and/or synergistic actions on the same target
tissue, this array of inflammatory mediators can elicit and sustain
a vascular leak, constrict smooth muscle, and initiate inflamma-
tory cell infiltration. MC mediator release can also be triggered by
innate signals, and although innate MC activation can be part of
a protective immunity to pathogens (reviewed in Marshall, 2004),
it also expands the variety of signals that can elicit pathologic
airway inflammation in asthma. Here, we review recent informa-
tion on MC activators beyond the antigen-induced crosslinking
of Fc3RI, as well as MC participation in initiating and amplifying
immunologic responses.
Mature MCs develop in peripheral tissues after transendothe-
lial migration of circulating MC progenitors (MCps). In mice, the
recruitment of MCps to the lung is dependent on the binding of
integrins a4b1 and a4b7 on MCp to endothelial vascular cell adhe-
sion molecule 1 (VCAM-1), the expression of which is regulated
by CXCR2 (Hallgren et al., 2007). The development of MCps and
their tissue maturation is dependent on the stimulation of Kit by
stem cell factor, which is a lineage-specific requirement. There
are two major MC subtypes, the connective tissue MC (CTMC)
sustained by SCF alone, and the intraepithelial mucosal MC
(MMC) that is dependent on costimulation by Th2 cytokines.
In addition to their different tissue distributions, these two MC
populations differ in the composition of their secretory granule
proteoglycans to which cationic proteases and amines are
bound. In rodents, the MMC secretory granule proteoglycan is
primarily composed of chondroitin sulfates that bear, in mice,
two b-chymases, mouse MC protease 1 (mMCP-1), and
mMCP-2, whereas the CTMC proteoglycan is composed pre-
dominantly of heparin glycosaminoglycans, which carry diverse
proteases that include chymases (mMCP-4 and mMCP-5), tryp-
tases (mMCP-6 and mMCP-7), and carboxypeptidase A. In
human MCs, the secretory granule proteoglycan has both chron-
droitin sulfate and heparin chains, and the MMC carry tryptase,
whereas the CTMC carry tryptase, chymase, and carboxypepti-
dase A (reviewed in Stevens and Adachi, 2007).
In vitro studies of rodent and of human MCs, generally
obtained by culture of progenitors, have demonstrated that
innate stimuli induce cytokines and LTC4 generation from MCs.
TNF-a, for example, can be generated by MCs in response to
signaling via TLR2 and TLR1, TLR2 and TLR6, TLR3, TLR4,
TLR7, and TLR9 (reviewed in Marshall, 2004). MC exocytosis
and LTC4 generation require the mobilization of calcium, which
is triggered by TLR2 and Dectin-1 signaling (Marshall, 2004;
Olynych et al., 2006). Whereas these studies highlight the wide
variety of innate signals that can activate MCs, they also under-
score the selectivity of mediator release in response to these
signals and the propensity for calcium mobilization and eicosa-
noid production to be restricted to TLR2 and CLR signaling, asImmunity 31, September 18, 2009 ª2009 Elsevier Inc. 429
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Buczynski et al., 2007; Suram et al., 2006). Although there is
now evidence that major crude allergens carry innate signals
for TLRs and CLRs, as well as epitopes for an IgE response (Bar-
rett et al., 2009; Hammad et al., 2009; Phipps et al., 2009), the
integrated role of allergen-derived innate signals in MC activation
is not known.
MCs can modulate DC antigen presentation and T cell activa-
tion. Murine BMMCs treated with IL-4 and the P815 and MC-9
MC lines spontaneously release exosomes, small endocytic
vesicles that contain soluble antigen as well as membrane-
bound MHCII and the costimulatory molecules CD80, CD86,
and CD40 (Skokos et al., 2003). Antigen-loaded exosomes are
potent activators of DCs and stimulate robust production of
serum IgG1 and IgG2a when injected s.c. into mice, which is
dependent on the MC exosomal proteins hsp60 and hsc70 and
the DC endocytic receptor for many heat shock proteins,
CD91. Another study has shown antigen transfer from MCs to
DCs by a distinct mechanism (Kambayashi et al., 2008). BMMCs
or freshly isolated peritoneal MCs ‘‘sensitized’’ with OVA-specific
IgE demonstrate endocytosis of IgE-bound OVA and activation
of CD4+ OT-II splenocytes that is dependent on apoptosis of
the BMMCs and their phagocytosis by BMDCs. MCs can provide
costimulation to activated T cells, given that BMMCs sensitized
with IgE and activated with antigen can augment the cell prolifer-
ation and cytokine production by cocultured CD3 mAb-activated
splenic T cells in a manner that is dependent on cell contact and
that is neutralized with antibody to OX40L, a molecule that is
expressed on activated BMMCs (Nakae et al., 2006).
The role of MCs in antigen-induced pulmonary inflammation
has been approached by use of the MC-deficient mouse strains
KitW/W-v or KitW-sh/W-sh with disruptions in the stem cell factor
receptor c-kit, which is required for normal MC growth and
survival. Because these strains have other hematologic abnor-
malities, (KitW/W-v are leukopenic and anemic [Galli et al., 2005];
KitW-sh/W-sh have splenomegaly, neutrophilia, and thrombocyto-
sis [Nigrovic et al., 2008]), MC engraftment achieved 8–12 weeks
after adoptive transfer of BMMCs is used for defining the MC
contribution to the disease phenotype. This approach does not
restore the number and location of mature MCs to the WT
phenotype. Nonetheless, a MC contribution was demonstrated
in a study using OVA i.p. sensitization without alum and in
repeated aerosol challenges over 9 weeks in both KitW/W-v and
KitW-sh/W-sh. The MC-deficient mice had substantially reduced
BAL eosinophils, neutrophils, and lymphocytes, pulmonary
eosinophilia, goblet cell metaplasia, and induced AHR that was
reversed with engraftment of WT BMMCs before initiating the
protocol (Yu et al., 2006). Engraftment of MC-deficient mice
with Fc3R1 g chain-deficient BMMCs, which cannot be activated
through either Fc3RI or FcgRIII, could not fully restore any aspect
of the phenotype, indicating a role for MCs in amplifying tissue
inflammation. In a model using intranasal OVA and LPS for sensi-
tization and OVA alone for challenge in KitW/W-v mice or the
WBB6F1 controls, the MC-deficient strain had reduced eosino-
philic inflammation in the BAL and lung histopathology. This
was reversed on adoptive transfer of BMMCs from C57BL/6
WT but not from Tlr4/ mice, suggesting that MC activation
by TLR4 can provide critical signals to promote eosinophilic
inflammation (Nigo et al., 2006). Although the MC mediator430 Immunity 31, September 18, 2009 ª2009 Elsevier Inc.was not identified, TNF-a is a prominent product of LPS-acti-
vated murine BMMCs (McCurdy et al., 2001), and TNF-a can
augment lung DC migration to draining lymph nodes after intra-
nasal injection of FITC-OVA, given that the number of FITC-OVA+
DCs in the draining lymph nodes of Tnf/, Tnfrsf1a/, MC-defi-
cient KitW/W-v or KitW-sh/W-sh, or KitW-sh/W-sh mice reconstituted
with BMMCs from Tnf/ mice was decreased as compared to
WT or KitW-sh/W-sh mice reconstituted with BMMCs from WT
mice (Suto et al., 2006). Thus, Fc3RI-activated MCs augment
tissue inflammation in the challenge phase and TLR4-activated
MCs can generate TNF-a for DC mobilization in the sensitization
phase. Nonetheless, the contribution of B cells, IgE, and MCs to
antigen-induced inflammation and AHR is strictly context depen-
dent such that MC-deficient mice display no defects in AHR or
pulmonary eosinophilia in antigen sensitization and challenge
protocols that use strong systemic adjuvant, high doses of
antigen, or prolonged challenges (Hamelmann et al., 1999;
Takeda et al., 1997; Williams and Galli, 2000).
A role for MCs in human asthma is evident in studies using
allergen challenge in sensitized asthmatics. Although the early
phase is associated with MC degranulation and an increase in
plasma histamine and urinary LTE4, both phases are attenuated
by pretreatment with sodium chromoglycate (an inhibitor of MC
degranulation), a 5-lipoxygenase inhibitor (preventing cys-LT
synthesis), a CysLT1 receptor antagonist, or antihistamines
(reviewed in Bradding, 2003). The MC contribution to asthma is
underscored by two recent findings. Omalizumab, an anti-IgE
mAb that blocks IgE binding to Fc3RI, decreases asthma exac-
erbations and allows reductions in corticosteroid use (Busse
et al., 2001; Milgrom et al., 1999), supporting a role for MCs in
chronic allergic inflammation. In an anatomic study of patients
with allergic asthma and with eosinophilic bronchitis, a disease
characterized by steroid-responsive cough and sputum eosino-
philia without airway hyperresponsiveness, bronchial biopsies
demonstrated equal numbers of submucosal MCs and eosino-
phils in both groups. In contrast, there was a selective increase
in tryptase and chymase positive MCs in the smooth muscle
layer of subjects with either atopic or nonatopic asthma. MC infil-
tration correlated with AHR, suggesting that localization of MCs
to the bronchial smooth muscle is a unique feature of airway
hyperresponsiveness (Brightling et al., 2002).
Eosinophils
Eosinophils are circulating granulocytes that are expanded in
bone marrow and that are recruited to peripheral tissues in the
settings of parasitic infection and allergic disease. The terminal
differentiation and mobilization of eosinophils from the bone
marrow is under the direction of IL-5. Eosinophils can generate
lipid mediators such as LTC4; cytokines such as IFN-g and
IL-2 (Th1) and IL-4, IL-5, IL-10, IL-13, and TNF-a (Th2); and
Th2 cell chemokines including CCL17 and CCL22 (reviewed in
Akuthota et al., 2008). Here, we review recent human studies
that highlight the importance of eosinophils in airway remodeling
(Flood-Page et al., 2003) and in asthma exacerbations in a partic-
ular subgroup of patients (Haldar et al., 2009; Nair et al., 2009),
and murine studies that extend its role beyond the classic
effector functions.
Eosinophils can modulate adaptive immune processes and
even act as antigen-presenting cells. Murine airway eosinophils
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elevated expression of MHCII, CD80, and CD86, can present
OVA antigen to memory T cells in vitro, and can stimulate activa-
tion and proliferation of memory DO11.10 T cells when trans-
ferred to previously sensitized recipients (Shi et al., 2000).
Ova-pulsed eosinophils from naive IL-5 transgenic mice can
activate naive DO11.10 TCR transgenic T cells when transferred
into WT recipients 24 hr after i.v. infusion of DO11.10 CD4+ cells
(Wang and Weller, 2008), demonstrating their ability to act as
professional APCs. However, human eosinophils cultured with
IL-3, IL-5, or GM-CSF can support the proliferation of T cell
clones to antigenic peptides, but not intact antigen, from tetanus
toxoid and from influenza hemaglutinin, demonstrating their
limited antigen-presenting function (Celestin et al., 2001).
Human eosinophil-derived neurotoxin (EDN) can activate human
monocyte-derived DCs to upregulate costimulatory molecules
and generate IL-6, IL-8, IL-12p70, and TNF-a in a MyD88-
dependent fashion (Yang et al., 2008). EDN acts as a TLR2
ligand and immunization of C57BL/6 mice with OVA and EDN
substantially augments anti-OVA IgG1 titers and splenic T cell
proliferation and cytokine production upon antigen restimulation
ex vivo, all of which is abrogated in Tlr2/mice. Eosinophils can
augment B cell activation in other settings. In a study of WT,
eosinophil-deficient dblGATA mice with deletion of the high-
affinity GATA binding site in the GATA-1 promoter and dblGATA
mice after i.v. infusion of eosinophils, splenic B cell activation
and the production of antigen-specific antibodies was depen-
dent on the presence of eosinophils (Wang and Weller, 2008).
Thus, by acting as an APC, augmenting DC antigen presenta-
tion, and enhancing immunoglobulin production, eosinophils
can have important effects on the generation of adaptive
immunity.
Two eosinophil-deficient mouse strains have demonstrated
a discrepancy in the requirement for eosinophils in antigen-
induced pulmonary inflammation. The PHIL mouse (Lee et al.,
2004), with the selective expression of diphtheria toxin A under
the EPO promoter, is on a C57BL/6 background, whereas the
dblGATA mouse (Humbles et al., 2004) is on the Balb/c back-
ground. Whereas PHIL mice had reduced antigen-induced
AHR in a protocol of OVA-alum sensitization and OVA challenge,
dblGATA mice did not. However, when dblGATA mice were
crossed to a C57 background, they also had attenuation of
antigen-induced AHR, which was reversed by eosinophil infu-
sion (Walsh et al., 2008). Both the PHIL and dblGATA mice on
a C57BL/6 background have a failure to recruit CD4+ T cells to
the lung with deficits in generation of pulmonary chemokines
CCL7, CCL11, and CCL24 and chemokines CCL17 and CCL22,
respectively (Jacobsen et al., 2008; Walsh et al., 2008). CD4+
T cell recruitment to the lung is restored either by infusion of
eosinophils (Jacobsen et al., 2008) or by i.n. delivery of eo-
taxin-1 during OVA challenge (Walsh et al., 2008), again demon-
strating that eosinophils are not simply terminal effector cells but
rather active participants during an adaptive Th2 cell response in
mice. Lastly, the Balb/c dblGATA mice had a decrement in peri-
bronchial collagen deposition and airway smooth muscle cell
proliferation (Humbles et al., 2004), and both PHIL mice and
C57BL/6 dblGATA mice had a decrement in PAS-positive goblet
cell metaplasia (Lee et al., 2004; Walsh et al., 2008), suggesting
a role for eosinophils in features of airway remodeling.Many clinical studies have documented a correlation between
pulmonary eosinophilia and asthma. Eosinophils are recruited to
the lung after segmental allergen challenge of atopic asthmatics.
Activated eosinophils are found in the induced sputum, BAL, and
mucosal biopsies of patients with asthma, and the degree of
peripheral blood and BAL eosinophilia correlates with disease
severity. Furthermore, the degree of eosinophilia in mucosal
biopsies correlates with inherent airway hyperresponsiveness
(reviewed in Bousquet et al., 2000). Increases in sputum eosino-
philia can predict the loss of asthma control, and several
randomized controlled trials have shown that adjusting inhaled
glucocorticoid doses to reduce sputum eosinophils can de-
crease exacerbations without an increase in total inhaled or
oral corticosteroid use (reviewed in Petsky et al., 2007). Although
these studies argue for the eosinophil as a marker of disease
activity, data supporting a pathobiologic role for eosinophils in
the clinical course of human bronchial asthma have been more
elusive until recently. Two randomized controlled trials using a
monoclonal antibody to IL-5 in patients with severe asthma
and persistent eosinophilia despite high doses of corticosteroids
have shown a reduction in clinical exacerbations associated with
reductions in peripheral blood and sputum eosinophils (Haldar
et al., 2009; Nair et al., 2009). Although this confirms a pathobio-
logic role for eosinophils in this highly selected clinical subgroup
of asthma, two prior studies of unselected asthmatic patients
demonstrated no benefit (Flood-Page et al., 2007; Leckie et al.,
2000), suggesting that eosinophils may play a critical role in a
small subset of patients. The possible benefit of anti-IL-5 in other
subsets of asthmatics (aspirin-intolerant asthmatics) with eosin-
ophilia remains to be determined. Notably, anti-IL-5 has been
shown to diminish the supepithelial deposition of extracellular
matrix proteins in mild asthmatics not on inhaled corticosteroids,
suggesting that, in parallel with the mouse data, eosinophils play
a role in airway remodeling (Flood-Page et al., 2003).
Basophils
Basophils are mature circulating granulocytes recruited to
peripheral tissues in the setting of allergic inflammation or hel-
minth infection. In the mouse, circulating basophils have been
difficult to assess by routine hematology, and studies have relied
on their characteristic ultrastucture with fewer, larger, and more-
uniform granules than eosinophils and PMNs. Murine basophils
have recently been identified by flow cytometry, on the basis
of their expression of CD49b (DX5+) and Fc3RI and the absence
of Kit, although the routine histology of this cell shows poor gran-
ulation (Lee and McGarry, 2007). Nonetheless, the ability to
identify this cell has led to an appreciation of new immune func-
tions as a facilitator of Th2 cell development and even as a
primary inducer of a Th2 cell response.
Mediator release from basophils can be triggered by both
Fc3RI-dependent and -independent mechanisms (reviewed in
Schroeder and Frederick, 2009). Whereas antigens can induce
specific crosslinking of Fc3RI to elicit histamine, lipid mediators,
and cytokines from human basophils, the HIV-1 glycoprotein
(gp) 120 and theSchistosomamansoni egg glycoprotein IPSE-al-
pha-1 can activate basophils in an IgE-dependent but antigen-
independent manner, via nonspecific interactions that crosslink
Fc3RI. Basophils can also be activated by C5a to degranulate
and generate LTC4 and IL-4, and by IL-33 and PGN to elicitImmunity 31, September 18, 2009 ª2009 Elsevier Inc. 431
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cytokine release. Comparable studies of degranulation, eicosa-
noid formation, and cytokine production from antigen stimulation
of IgE sensitized mouse basophils are lacking but cytokine
production is apparent in the studies detailed below.
Recent murine studies have highlighted a role for basophils in
the effector phase of chronic allergic inflammation in vivo. The
subcutaneous administration of TNP-conjugated OVA into the
ear of Balb/c or C57BL/6 mice passively sensitized with a prior
i.v. injection of TNP-specific IgE leads to a triphasic ear swelling
with a dramatic third cellular phase at 48 hr consisting of eosin-
ophil and neutrophil infiltration in the tissue (Mukai et al., 2005).
This third phase is abolished in FcRg-deficient mice that lack
Fc3RI signaling, but re-established in BM chimeras with a DX5+
basophil-enriched population for reconstitution of irradiated
FcRg-deficient recipients. In a confirmatory study, the same
investigators showed that depletion of basophils with the baso-
phil-specific antibody BA103 24 hr prior to passive sensitization
and challenge abrogated the third phase, but left the immediate
and late-phase responses intact (Obata et al., 2007).
Basophils can also participate in immunoglobulin production.
In a study in which mice were sensitized and challenged with
APC, PE, or pneumococcal surface protein A (PspA), depletion
of basophils prior to the challenge with an antibody to the alpha
chain of Fc3RI (MAR-1) decreased antigen-specific antibody
production in all Ig subgroups and significantly increased sepsis
in mice that had been vaccinated to PspA and infected with
S. pneumoniae (Denzel et al., 2008).
A role for the basophil in facilitating Th2 cell immune responses
has recently been uncovered. Mice with a targeted deletion in the
gene encoding the interferon regulatory factor 2 (IRF-2) tran-
scription factor exhibit a Th2 cell-polarized phenotype with
high serum IgE titers and robust ex vivo IL-4 production by
splenic CD4+ T cells. This phenotype is associated with sponta-
neous expansion of the splenic Fc3RI+DX5+KitB220 basophil
compartment (Hida et al., 2005). In ex vivo coculture experi-
ments, splenic cell preparations from IRF-2-deficient mice
directed OT-II TCR transgenic T cells to produce IL-4. IL-4
production by OT-II cells was diminished with basophil depletion
and was abrogated by anti-IL-4, revealing a role for basophils in
Th2 cell development. In a unique approach to recognizing baso-
phil function, the Fc3RI+DX5+Kit cell population in liver and
bone marrow was expanded by administration of IL-3 to WT
mice through a miniosmotic pump (Oh et al., 2007). These baso-
phils could induce naive PCC peptide-stimulated 5C.C7 trans-
genic CD4+ T cells to produce IL-4 in a dose-dependent fashion,
and basophil-mediated skewing was abrogated when Il4/
basophils were used. Further, naive transgenic T cells that
were adoptively transferred into Rag2/ mice primed with
IL-3, but not untreated controls, responded to challenge with
PCC peptide by developing CD4+ IL-4+ Th2 cells, demonstrating
that in vivo Th2 cell development was augmented in an environ-
ment with IL-3-expanded basophils (Oh et al., 2007). Another
study used the ‘‘4get’’ mice, which contain a bicistronic
construct encoding enhanced green fluorescent protein in the
Il4 locus that can be used to track IL-4 competent cells in vivo
during the development of Th2 cell immune responses (Sokol
et al., 2008). Immunization of these mice with the model protease
allergen papain generated CD4+DX5IL-4-eGFP+ Th2 cells in the432 Immunity 31, September 18, 2009 ª2009 Elsevier Inc.draining lymph node on day 4 that were preceded by TSLP-
producing DX5+IL-4-eGFP+ basophils. Th2 cell generation was
abrogated with basophil depletion with the MAR-1 antibody or
with a neutralizing antibody to TSLP, thus demonstrating that
basophil-derived IL-4 and TSLP are critical checkpoints in the
development of Th2 cell immunity.
Recent studies have expanded the function of basophils to
include antigen presentation. In an in vitro system using TCR
Tg DO11.10-‘‘4get’’ T cells and OVA peptide, the addition of puri-
fied bone marrow-derived basophils (BMB) to the culture system
in the absence of any other APC produced Th2 differentiated
cells, as measured by IL-4-eGFP expression in T cells. This
effect was abrogated by antibodies to MHC II and by using baso-
phils from Il4/mice (Sokol et al., 2009). Th2 cell generation was
augmented in the presence of papain, which increases basophil
expression of MHC II, IL-4, and TSLP, indicating an innate
response of the basophil that augments direct presentation of
a soluble antigen. Basophils were able to generate Th2 cell
immune responses in vivo in the absence of other contaminating
APCs because OVA-pulsed basophils transferred into C57BL/6
WT mice or Ciita/ mice (which do not express MHC II) induced
comparable production of IL-4 by antigen-restimulated CD4+ LN
T cells ex vivo. In a complementary study, BMB and splenic
NTNB Fc3RI+Kit basophils primed by Strongyloides venezue-
lensis infection of WT mice were able to act as APCs and
generate Th2 cells in the DO11.10-OVA system (Yoshimoto
et al., 2009). In a nontransgenic system, WT Balb/c mice sensi-
tized with DNP-OVA- and anti-DNP-IgE-treated basophils and
challenged 4 days later with OVA protein had elevated serum
OVA-specific IgE and IgG1 titers and increased production of
IL-4 and IL-13 by OVA-restimulated splenic CD4+ T cells ex
vivo. Conversely, basophil depletion with the MAR-1 antibody
prior to i.v. immunization with DNP-OVA/anti-DNP Ag-IgE in
WT mice decreased OVA-specific IgG1, IL-4, and IL-13 produc-
tion from OVA-restimulated splenic CD4+ T cells. A different
study using transgenic mice with MHC II expression restricted
to CD11c+ cells revealed impaired generation of LN IL-4, IL-5,
and IL-13, persistent histologic inflammation, and a higher
worm burden after infection with Trichuris muris (Perrigoue
et al., 2009). Conversely, CD11c-DTR mice with DT-dependent
CD11c+ cell depletion had no impairment in Th2 cytokines or
worm expulsion, revealing that DCs were neither sufficient nor
required for productive helminth immunity. Basophils were
identified in the spleen of infected WT mice, and depletion of
basophils with the MAR-1 antibody resulted in decreased IL-4
transcript from colonic tissue, increased inflammation, and
increased worm burden, suggesting that basophils are critical
for Th2 cell-dependent immunity. Taken together, these recent
studies in mice reveal that basophils can direct a T cell response
to Th2 cell polarization in vitro and in vivo, but there are no data
showing direct Ag presentation by these cells in allergic pulmo-
nary inflammation.
Basophils are detected in the lung sections of patients with
fatal asthma (Kepley et al., 2001) and in the bronchial biopsies
of atopic asthmatics during the late phase after allergen chal-
lenge (Macfarlane et al., 2000). Basophils recovered from the
BAL of mild asthmatics after segmental allergen challenge
produce IL-4 protein assessed by flow cytometry on freshly
isolated cells and by ELISA on supernatants from short-term
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Figure 1. Innate Cells and Their Mediators
Modulate the Development of Th2 Cell
Immune Responses
Activated eosinophils (Eos) release eosinophil-
derived neurotoxin, which acts at DC TLR2 to
mature DCs, to generate IL-6, IL-8, IL-12p70, and
TNF-a, and to enhance the production of
antigen-specific Th2 cell cytokines and serum
IgG1. MC-derived TNF-a facilitates DC migration
to the lymph node. MCs facilitate DC antigen
presentation by taking up antigen and either
releasing it in exosomes or apoptosing for subse-
quent DC phagocytosis and activation. Activated
MCs and basophils produce TSLP, which upregu-
lates OX40L on DCs for the subsequent generation
of Th2 cell immunity. In the lymph node, basophils
direct Th2 cell development with the generation of
IL-4 and TSLP. Basophils can present soluble
antigen to direct Th2 cell development, which is
augmented by the presence of antigen-specific
IgE and critical to the generation of Th2 cell immu-
nity during helminth infection. IL-33, IL-25, and
TSLP potentiate the proliferation of committed
Th2 cells as well as their cytokine production.culture in medium alone (Schroeder et al., 2001), and IL-4 mRNA
and protein colocalizes with basophils in the bronchial mucosa
of atopic asthmatics after segmental allergen challenge. Baso-
phil activation, as assessed by CD69 expression, is upregulated
in basophils from the peripheral blood of asthmatics as
compared to normal controls (Yoshimura et al., 2002). The use
of anti-IgE in patients with allergies and atopic asthma results
in a rapid decrement in serum IgE and the subsequent gradual
reduction of Fc3RI on MCs and basophils. In a study of patients
with perennial allergic rhinitis, treatment with anti-IgE decreased
Fc3RI surface expression on human basophils from pretreatment
levels of 220,000 receptors per cell to 8,000 receptors per cell
and correlated with a 90% reduction in basophil degranulation
in response to house dust mite antigen in vitro (MacGlashan
et al., 1997). In patients with seasonal allergic rhinitis, free IgE
titers were reduced by 96% after 3 days of omalizumab, but
a reduction in nasal PD30 response to ragweed challenge was
only noted after 14 days of treatment and this was associated
with a 70% reduction of Fc3RI expression on circulating baso-
phils (Lin et al., 2004). Thus, whereas studies using omalizumab
suggest a role for basophils and mast cells in Fc3RI-mediated
allergic responses, their contributions based on the mouse
studies could be cooperative or distinct, with the basophil impli-
cated in facilitating Th2 cell adaptive immune responses by
supplying IL-4 and/or TSLP or by acting as an APC for select
allergens.
Concluding Remarks
Asthma is a heterogeneous disease with a variable clinical
presentation, association with atopy, profile of recruited inflam-
matory cells, and response to targeted therapies, suggesting
involvement of immune pathways beyond the canonical Th2
cell paradigm. An emerging body of evidence from human
in vitro studies and mouse models demonstrates that innate
stromal and hematopoietic effectors cells can promote CD4+Th2 cell immune responses by activating DCs, supplying IL-4
and TSLP, acting as APCs, and directly activating committed
memory Th2 cells (Figure 1). However, these cells can them-
selves generate the full repertoire of Th2 cytokines, lipid media-
tors, eosinophilic, and neutrophilic inflammation that is the
hallmark of asthma (Figure 2). Thus, whereas the generation of
inflammatory mediators from epithelial cells, iNKT cells, MCs,
eosinophils, and basophils has previously been viewed as a
mechanism to amplify established inflammation, complex aller-
gens that provide immunogenic epitopes and PAMPs for TLR,
CLR, and/or NLR signaling can activate these innate cells to
initiate the development of innate and adaptive host immune
responses. Our current understanding of these innate re-
sponses, even in mice, has substantial gaps. They include the
distinction between studies with pure proteins (with or without
adjuvants) and those conducted with clinically relevant allergens
or viral models of airway inflammation; the contribution of
neutrophils, if any, to these innate responses; the role of myeloid
DCs and macrophages, which can produce leukotrienes and
inflammatory mediators in response to PAMPS, allergens, and
chitin (Barrett et al., 2009; Reese et al., 2007; Suram et al.,
2006) as effector cell participants in allergic inflammation
(Figure 2); and the delineation of which innate pathways are rele-
vant in the absence of T and B cell immunity. It seems reasonable
to consider the roles and magnitude of these innate signals in hu-
mans with nonatopic asthma, in viral exacerbations of asthma,
and in neutrophil-predominant asthma. What is clear is that
exposure of the lung to diverse environmental elements can acti-
vate many pathways to airway inflammation and that many new
potential targets for therapy are emerging from basic research.
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